363 results about "Clinical disease" patented technology

The invention discloses a stem cell exosome patch and its preparation method and application and belongs to the field of tissue engineering. The stem cell exosome patch comprises the following steps: stem cell is cultured and stem cell exosome is collected; a patch scaffold is prepared; and the exosome obtained is attached to the patch scaffold to prepare the stem cell exosome patch. the stem cell exosome patch obtained has natural and easily available drug sources; action site accuracy of the exosome patch can be guaranteed; effective acting time of the patch after implantation can be prolonged; and potential safety hazard can be avoided to a great extent. Through the method, the stem cell exosome patch with good biological characteristics can be obtained. The invention is a new breakthrough of establishing a biological patch in the field of tissue engineering. Meanwhile, the product also provides a feasible scheme for clinical treatment of diseases. The principle of the invention is scientific and reliable, and the technology is simple and flexible.

The invention belongs to a clinical administration management system and in particular discloses a clinical safe and reasonable administration decision supporting method. The system at least comprises a clinical reasonable administration standard database, information input equipment and a doctor advice decision unit. When patient pathological information is input into the doctor advice decision unit through the information input equipment, the doctor advice decision unit compares and discriminates the patient pathological information and the pathological information of common clinical diseases and frequent diseases stored in the clinical reasonable administration standard database; administration standard doctor advice information is displayed through the doctor advice decision unit; the administration standard doctor advice information of the doctor advice decision unit is further selected through the information input equipment; the doctor advice decision unit further compares and discriminates the selected administration standard doctor advice information through a safe administration monitoring database; and the doctor advice decision unit acquires a confirmed doctor advice and supplies the advice to a patient. The invention provides the clinical safe and reasonable administration decision supporting method capable of quickly, economically and effectively monitoring disorder, tentativeness and experientialism of clinical administration.

The invention relates to a method for diagnosing pre-symptomatic metabolic syndrome in a subject, wherein said method comprises determining the expression level of a gene represented by a sequence selected from the group consisting of SEQ ID NO: 1-18 in a subject. The invention described target genes for preventing or stopping further progress of metabolic syndrome into clinical disease states.

The invention belongs to a clinic drug use management system, and particularly relates to a clinic safe and reasonable drug use decision supporting method. The clinic drug use management system at least comprises a clinic reasonable drug use standard database, information input equipment and a doctor advice decision unit, wherein when the pathological information of a patient is input to the doctor advice decision unit through the patient information input equipment, the doctor advice decision unit compares and discriminates the pathological information of the patient with the pathological information of common clinical diseases and high-incidence diseases stored in the clinic reasonable drug use standard database, drug use standard doctor advice information is displayed through the doctor advice decision unit, the drug use standard doctor advice information displayed by the doctor advice decision unit is further screened through the information input equipment, and the screened drug use standard doctor advice information is further compared and discriminated by the doctor advice decision unit through a safe drug use monitoring database, and confirmed doctor advice is obtained through the doctor advice decision unit and provided to the patient. The clinic safe and reasonable drug use decision supporting method can rapidly, economically and effectively monitor disordering, attempt and experience trends of clinic drug use.

The invention relates to an in vitro diagnostic kit for the determination of activated partial thromboplatin time (APTT) in clinical test. The invention consists of a partial thromboplatin reagent and a calcium chloride solution, which is used for the detection of the defects of the intrinsic coagulation pathway factors and the screening test of the related inhibitors, and the invention is also a primary means for the current coagulation factor and heparin anticoagulant treatment and the detection of lupus anticoagulant. The invention has the advantages of long stability time and good repeatability of the partial thromboplatin reagent after a re-dissolution, at the same time, the invention has better consistency of the measurement results of a blood coagulation analyzer by using an optical method and a magnetic bead method, therefore, the invention is applicable to large, medium and small hospitals, and the test results of different hospitals have comparability, therefore the invention has important meaning for implementing the one general report of test reports, provides the reliable experimental data for the clinical diagnosis and the treatment of diseases and improves the efficiency and value of the basic studies of thrombosis and hemostasis.

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs. Control of ASF has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. Among viral genes reported to be involved in virulence are components of the multi gene family (MGF). Here we report the construction of a recombinant ΔMGF virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G ΔMGF administered intramuscularly (IM) to swine at either 102 or 104 HAD50 are completely attenuated; the inoculated animals are completely asymptomatic. Animals infected with 102 or 104 HAD50 of ASFV-G ΔMGF are protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.

The invention discloses a particle analyzer and a particle analysis method. The analyzer comprises a flow chamber through which a sample liquid containing particles flows, a drive unit which is used for driving the sample liquid to flow through the flow chamber, a light irradiation unit which is used for emitting specific spectra to the particles in the flow chamber, a magnification imaging unit and a feature extraction analysis unit, wherein the magnification imaging unit acquires particle images formed under the specific spectra, magnifies and then outputs the images to the feature extraction analysis unit; and the feature extraction analysis unit extracts image features, identifies and classifies the particles according to the features. The analysis method comprises the steps of driving the sample liquid containing the particles to flow through the flow chamber, emitting the specific spectra to the particles in the flow chamber, acquiring the particle images formed under the specific spectra, magnifying the images, extracting the image features, identifying and classifying the particles according to the features. Clinical diseases needing to depend on images for analysis can be accurately judged through the invention.

The invention discloses a video heart rate detection method removing interference of ambient light variation. Firstly a face area-of-interest data set and a background area data set are obtained, a united blind source separation technology is utilized to process the two data sets, and signal sources of ambient light variation that the data sets both have are extracted and set to zero, thereby obtaining a face area-of-interest data set free of interference of ambient light variation; secondly, face area-of-interest data of an optimal color channel is selected, and an ensemble average empirical mode decomposition method is utilized to obtain intrinsic mode components; and then all local intrinsic mode components of which frequency corresponding to maximum amplitude values are in a set heart rate range are determined to be a candidate intrinsic mode component set, the intrinsic mode component corresponding to the largest maximum amplitude value is determined to be the optimal intrinsic mode component, and a video heart rate is obtained through a peak detection algorithm. The video heart rate detection method provides a relatively accurate algorithm for non-contact heart rate detection, and has important application prospects in the aspects of clinical disease diagnosis and daily medical care.

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

The invention discloses a method for simultaneously detecting forty types of amino acids in dried blood spots, blood and urine. The method comprises the following steps of firstly, pretreating a biological sample by a simple liquid and liquid extracting method; performing chromatographic separation and mass spectrometric detection; using the relative retention time and qualitative ions as the qualitative basis for each type of amino acid, and using a standard product to manufacture a standard curve for quantifying. The method has the advantages that the accuracy and validity of the method shall be studied by three levels of quality control products, so as to avoid the distortion of detection results; the forty types of non-derived amino acids in one sample can be simultaneously detected bya HPLC-MS / MS (high performance liquid chromatography-mass spectrograph) technique for the first time; the operation is simple, convenient and rapid, the flux is high, and the cost is low; the level of amino acids in a human body can be effectively monitored in real time; the enough basis is provided for the clinical disease diagnosis; the method is suitable for being clinically popularized and applied.

An tool and method is disclosed to assess disease activity and to classify complex diseases using basic clinical data. The tools and methods allow identifying and consulting affected individuals based on comprehensive bedside examinations and thus provide a basis for the personalized management of complex diseases.

The invention discloses high-fat feed and application thereof in building an animal model with non-alcoholic fatty liver. The high-fat feed comprises the following raw materials in mass percent: 80.5% of rat breeding feed, 10% of egg, 7% of lard oil, 2% of cholesterol and 0.5% of No.3 bile salt. The model built in the invention can subsequently experience former three stages in the development ofthe clinical disease course of the non-alcoholic fatty liver: simple fatty liver, steato hepatitis and fibrosis. The model is used for studying the pathogenesis as well as the development mechanism of the non-alcoholic fatty liver, studying the prevention and treatment of the non-alcoholic fatty liver at different stages, and particularly for screening new medicines for preventing and treating fibrosis of the non-alcoholic fatty liver, screening measures for preventing and treating fibrosis of the non-alcoholic fatty liver and objectively evaluating the methods for preventing and treating thenon-alcoholic fatty liver at each stage.

A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.

The invention provides a compound betamethasone suspension injection, which is a compound preparation composed of low-solubility betamethasone dipropionate and high-solubility betamethasone sodium phosphate. Long-lasting, it can be used for the treatment of musculoskeletal and cartilage tissue diseases, allergic diseases, skin diseases, collagen diseases, tumors and other clinical diseases.

The invention provides a method and device for evaluating the efficacy of a chronic disease drug. The method includes the steps of determining a clustering method; clustering real feature data of a case according to the clustering method, and obtaining drug use information and diagnostic information corresponding to different categories; and analyzing the efficacy of each drug according to the drug use information and diagnostic information corresponding to the different categories. The method provided by the invention can be applied to the theoretical research related to the evaluation of theefficacy of the chronic disease drug, and can also be applied to the prediction, early warning and drug recommendation of the clinical disease complications simultaneously. The analysis results are detailed, accurate, small in error. The larger the number of data samples is, the greater the credibility of the analysis results is. Great convenience is brought to medical workers in analyzing and judging the treatment of chronic diseases. The method is of great significance for the analysis of biological and medical related fields.

The invention relates to an in vitro amplification and low-temperature storage method for regulatory T cells of umbilical cord blood. The method comprises the following steps of: separating a CD4+CD25+T cell group rich in the regulatory T cells from the umbilical cord blood; amplifying the enriched CD4+CD25+T cell group to obtain high-purity regulatory T cells; and storing the amplified regulatory T cells in liquid nitrogen at a low temperature to serve as third-party unrelated donor regulatory T cells for treating clinical diseases. The method has the advantages that: a large quantity of regulatory T cells can be obtained from the umbilical cord blood and stored for a long term in the liquid nitrogen, can meet the requirements of clinic for regulatory T cell products, and are used for treating graft versus host disease, organ transplantation rejection and autoimmune disease.

The invention discloses a high-precision intelligent pulse diagnostic instrument, comprising a frame component, a probe component and an information acquisition system. The frame component mainly comprises a pulse rest part at the bottom and a frame part arranged above the pulse rest part; the probe component at least comprises four intelligent fingers arranged in parallel; each intelligent fingerhas three driving units and a composite sensing unit. The frame part is connected with the probe component and is used for allowing the probe component to rotate around the arm or linearly move parallelly to the arm, and the arm is placed on the pulse rest part and is driven to rotate or lift; an image acquisition module and an image analysis and positioning module allow positioning and acquiringto be carried out. The high-precision intelligent pulse diagnostic instrument allows automatic alignment, pressure application and pulse signal acquisition to be carried out according to the method of 'five belts, six zones and seven layers', can provide pulse diagnosis for 'five sections and twelve syndromes', and has the advantages of high precision, repeatability and reproducibility; the high-precision intelligent pulse diagnostic instrument is applicable to early warning and diagnosis for clinical diseases, and the problems are effectively solved that, for instance, existing like instruments have low acquisition precision and incomplete acquired signals.

The invention discloses a kit for quantitatively detecting a BCR / ABL mRNA level. The kit comprises a standard product which is used for manufacturing a standard curve, an inner reference gene real-time quantitative PCR system and at least one of the following three real-time quantitative PCR systems: an M-type BCR / ABL real-time quantitative PCR system, m-type BCR / ABL real-time quantitative PCR system and a mu-type BCR / ABL real-time quantitative PCR system. The kit can accurately, quickly and quantitatively detect various BCR / ABL mRNA levels, is used for diagnosing chronic myelogenous leukemia and acute lymphoblastic leukemia expressed by BCR / ABL and monitoring minimal residual diseases in a treatment process, and provides an important molecular basis for accurate diagnosis of clinical diseases, determination of a treatment proposal, curative effect evaluation and prognosis.

The invention discloses a chromogenic medium for detecting salmonella, which belongs to the fields of food safety and clinical microbiological detection. The culture medium contains agar, peptone, beef extract powder, sodium chloride, a surfactant, cholate, an enzyme inducer, an octoate enzyme chromogenic substrate, a beta-galactosidase chromogenic substrate, a hexosaminidase chromogenic substrate and robiocina. The chromogenic medium disclosed by the invention is used for detecting salmonella, has high detection sensitivity and high specificity, and can be used for initially identifying strains directly according to the color of a colony; the chromogenic medium has high operability, and suitable for treating large-reflux samples, and can be used for comprehensively, systematically and accurately detecting and initially identifying salmonella in food production, clinical disease diagnosis and the environment; and a new way is provided for rapid detection of microorganisms.

The invention discloses a blood sample level dependence functional magnetic resonance signal fluctuating frequency clustering analysis method which is characterized by comprising the following steps: step 1, pretreatment analysis is performed on resting state data collected from a magnetic resonance machine; step 2: Hilbert-Huang transform is adopted for decomposing the pretreated signals, so as to obtain intrinsic mode functions with different frequencies; the Hilbert-Huang transform comprises two steps of empirical mode decomposition and Hilbert transform; step 3, quantitative indexes of different frequency components are calculated; step 4, clustering of different voxels in a brain is performed by taking the quantitative indexes in the step 3, as a basis for classification and statistical analysis to the different indexes is performed. The method solves the problem of insufficiency of data drive frequency analysis methods in the fMRI research field, an iconography analytical method is provided for basic science and clinical researches and meanwhile new quantitative indexes and physiological markers are provided for clinical disease diagnosis and pathological mechanisms.

The invention discloses an Echarts-based hierarchical diagnosis and treatment analysis and data visualization system, comprising a data cleaning module used for acquiring information about patients, diseases and hospitals from medical record information, a patient analysis module used for analyzing medical treatment of the patients, transfer treatment, characteristics of the patients, influence factors of choices for the hospitals and the like from the levels of provinces, cities, districts and counties, a disease analysis module used for analyzing disease regional characteristics, disease seasonal characteristics, cross-level disease treatment characteristics, different place disease treatment characteristics, common disease treatment characteristics, slow disease treatment characteristics and the like from the levels of provinces, cities, districts and counties, a hospital analysis module used for analyzing sources of the patients clinically accepted by the hospitals, characteristics of the clinically accepted patients and structural characteristics of the clinical diseases from the levels of provinces, cities, districts and counties, and a data visualization module used for realizing analysis result visualization by means of drawing a map, a dynamic flow graph, a thermodynamic diagram, a pie chart or a histogram. After the Echarts-based hierarchical diagnosis and treatment analysis and data visualization system is adopted, a hierarchical diagnosis and treatment analysis process is more systematized, and data analyzing and processing efficiency is improved.

An object of the present invention is to provide apparatuses for examining / diagnosing clinical disease of cancer, systemic lupus erythematosus (SLE), or antiphospholipid antibody syndrome. Blood, blood-derived component, urine, sweat, nail, skin, or hair is irradiated with light having a wavelength of 400 to 2,500 nm or a part of the range, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic absorbance data, and afterward a previously prepared analysis model is used to analyze the absorbance over the whole wavelengths or at a specific wavelength for the measurement to allow the achievement of the object.

The invention discloses a data analysis method for multi-modal big data of clinical diseases. The data analysis method includes the steps: acquiring historical big data corresponding to disease types from a medical system; designing a multi-density quantizer according to change rates of the historical big data in various modes; extracting characteristic information corresponding to the disease types from the historical big data by a multi-modal data mining method and a convolutional neural network method; deducing the dynamic evolution law of individuals infected by the disease types in the historical big data according to the characteristic information; acquiring performance evaluation indexes of real-time data according to the dynamic evolution law of the individuals. Therefore, the method effectively overcomes limitation of single-modal data, dangerous factors of diseases can be taken into full consideration, more detailed and accurate clinical diagnosis standards are provided for hospitals, the dynamic evolution law of the individuals can be given, decision basis and technical support are provided for early diagnosis and early treatment of the diseases, and diagnosis efficiency and diagnosis and treatment quality are improved.

The invention relates to a magnetic sensing identification method for high-flux multi-channel low-abundance biomolecules, and belongs to the technical field of biomolecule identification. The invention mainly aims at an immunolabelling biomolecule detection, monitoring and identification method based on systems such as antigens-antibodies, cell factors-cell factor acceptors, bioactive peptides-acceptors, biotin-avidin and chiral molecules. A biomolecule probe and detection system consists of superparamagnetic particles and high-performance magnetic sensors. The magnetic sensing identification method can be applied to the application fields of biology, medicines, food safety and the like, and can be used for biomolecule identification, detection and monitoring, clinical disease diagnose, food safety detection and virus and germ detection.

The invention discloses a kit used for detecting the polymorphism of genes related to Warfarin and Clopidogrel personalized medication and application thereof. The kit comprises a general chip, a first primer combination and a second primer combination, wherein each primer combination unit in the first primer combination is used for identifying one polymorphism site of the genes related to Warfarin medicine resistance, and each primer combination unit in the second primer combination is used for identifying one polymorphism site of the genes related to Clopidogrel medicine resistance. The kit has the advantages of being high in integration degree, sensitivity, specificity, reliability and operability and wide in application range, detection results are stable, a use method is fast and convenient, and automation of the kit is easy to achieve; the kit can be used for detecting gene mutation, analyzing gene polymorphism and the like and is suitable for gene analysis fields such as mutation detection of clinical diseases, pharmacogenomics analysis and medicolegal expertise.

The invention discloses a portable intelligent TCM pulse diagnosis instrument with multi-probe, comprising the frame components, the probe components and an information acquisition system. The frame components consist of the wrist cushion component and the frame component. The probe component is connected to the frame component and the three-degree-of-freedom movement of the probe component in a plane perpendicular to the arm is achieved by the movement mechanism. The user can put the arm on the writ cushion component and adjust the position and angle when needed. The information acquisition and the positioning of the position and the posture of the arm are realized by the image acquisition module and the image analysis and positioning module in the information acquisition system. According to the method of "five belts, six zones and seven layers", the instrument is capable of locating the pulse automatically before automatic applying pressure to the pulse and collecting the pulse signal automatically, thereby realizing the diagnosis for the meridian disease. So the instrument is characterized of being highly precise, repeatable, reproducible and flexible. The instrument can be used for early warning and diagnosis of clinical diseases, effectively solving the problems of low acquisition accuracy, incomplete acquisition signals and the bulky body of the same instruments.

The invention discloses a fluorescent quantitative PCR primer and probe to detect human Boca virus in the microbe detecting technical domain (biological engineering product detetion), which is characterized by the following: designing the primer and probe according to the NC 007455 on the GenBank; making the length of oligonucleotide sequence between 20 and 30; displaying higher sensitivity and specificity; fitting for multiple facets based on the primer and probe, such as clinical disease diagnosis, antiviral drug sieving, environment monitoring and estimation, hygienic monitoring and port hygienic quarantine, epidemiologic survey and so on.

The present invention relates to a quantitative detection analysis method of human plasma DNA level. Said method includes the following steps: selecting artificially-synthetic exogenous DNA series whose extraction efficiency is identical to or similar to that of human plasma DNA, but they are non-homologous, selecting housekeeping gene beta actin as determination gene, inserting artificially-synthetic exogenous DNA into carrier pMD18T and placing it in the bacteria to make culture, making blue and white spot screening, colony PCR identification, enzyme-cutting into linearity, placing the above-mentioned material into plasma, adopting double fluorescent quantitative gene amplification, fluorescent groups are respectively FAM and HEX, extracting known exogenous positive plasmid recovery efficiency, using computation formula to make computation so as to obtain the quantity of plasma DNA.

Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.

African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. We have constructed a recombinant Δ9GL / ΔUK virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. In vivo, ASFV-G Δ9GL / ΔUK administered intramuscularly to swine even at relatively high doses (106 HAD50) does not induce disease. Importantly, animals infected with 104 or 106 HAD50 are solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.